<DOC>
	<DOCNO>NCT00138125</DOCNO>
	<brief_summary>RATIONALE : Estrogen cause growth breast cancer cell . Hormone therapy use fulvestrant may fight breast cancer lower amount estrogen body make . Monoclonal antibody , trastuzumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . It yet know whether give fulvestrant together trastuzumab effective give fulvestrant trastuzumab alone treat breast cancer . PURPOSE : This randomized phase II trial study well fulvestrant and/or trastuzumab work first-line therapy treat postmenopausal woman stage IV breast cancer .</brief_summary>
	<brief_title>Fulvestrant and/or Trastuzumab First-Line Therapy Treating Postmenopausal Women With Stage IV Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare overall objective response rate postmenopausal woman estrogen receptor ( ER ) - and/or progesterone receptor ( PR ) -positive , HER2/neu-overexpressing stage IV breast cancer treat first-line therapy comprise fulvestrant and/or trastuzumab ( Herceptin® ) . Secondary - Compare duration response patient treat regimen . - Compare overall survival patient treat regimen . - Compare antitumor activity regimens , term time disease progression , patient . - Compare clinical benefit regimens patient . - Determine safety toxicity regimens patient . - Correlate HER2/neu expression ER and/or PR expression response patient treat regimen . OUTLINE : This randomize , control , open-label , multicenter study . Patients stratify accord prior adjuvant endocrine therapy ( yes v ) . Patients randomize 1 3 treatment arm . - Arm I : Patients receive fulvestrant intramuscularly day 1 15 course 1 day 1 subsequent course . - Arm II : Patients receive trastuzumab ( Herceptin® ) IV 30-90 minute day 1 , 8 , 15 , 22 . - Arm III : Patients receive fulvestrant arm I combination trastuzumab arm II . In arm , course repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 8 week . PROJECTED ACCRUAL : A total 120 patient ( 40 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Female patient , postmenopausal , define woman fulfil one follow criterion : Age 60 year old Age 45 year old amenorrhea &gt; 12 month intact uterus Folliclestimulating hormone estradiol level within postmenopausal range Having undergone bilateral oophorectomy Histologically cytologically proven adenocarcinoma breast Subjects must archive rumor tissue available compare clinical response tumor expression biomarkers , HER2 , ER PR ; archive tissue use confirm HER2 , ER PR status , result use determine subject eligibility study HER2positive disease ERpositive and/or PRpositive disease ECOG performance status 02 Life expectancy &gt; 24 week Left ventricular ejection fraction &gt; low limit normal No prior chemotherapy , endocrine therapy , Herceptin , biologic investigational therapy metastatic breast cancer No two prior endocrine agent adjuvant set single sequentialtherapy permit , prior Faslodex therapy permit . A 1month treatmentfree period require prior receive first dose trial treatment Prior adjuvant chemotherapy permit Prior adjuvant Herceptin permit At least 1 month since prior surgery , radiotherapy , endocrine therapy , complete recovery effect intervention Patients must end hormone replacement therapy least 1 month prior receive first dose trial therapy Patients treat bisphosphonates may enroll , heir bone lesion assessable disease progression Patient accessible willing comply treatment followup Patient willing provide write informed consent prior performance studyrelated procedure Required laboratory value : Absolute neutrophil count &gt; 1.5 x 10^9/L Hemoglobin &gt; 10g/dL Platelet count &gt; 100 x 10^9/L Creatinine &lt; 2.0 mg/dL Total bilirubin &lt; 1.5 x upper limit normal AST ALT &lt; 2.5 x ULN Prior chemotherapy , hormonal therapy , Herceptin investigational therapy metastatic breast cancer Prior treatment Faslodex Concurrent therapy nonprotocol anticancer therapy Current prior history brain metastasis History malignancy within past 5 year , exception nonmelanoma skin cancer carcinomainsitu cervix Clinically significant cardiovascular disease , New York Heart Association Class II great congestive heart failure , serious cardiac arrhythmia require medication Prior exposure &gt; 360 mg/m2 doxorubicin liposomal doxorubicin , &gt; 120 mg/m2 mitoxantrone , &gt; 90 mg/m2 idarubicin , &gt; 720 mg/m2 epirubicin Active , uncontrolled infection require parenteral antimicrobial The presence medical psychiatric disorder , opinion treat physician , would contraindicate use drug protocol place subject undue risk treatment complication Inability comply study protocol followup procedure Known hypersensitivity drug use protocol active inactive excipients Faslodex History bleed diasthesis Longterm anticoagulant therapy antiplatelet therapy , warfarin</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>